Latest Ratios: P/E Ratio 57.3x · EV/EBITDA N/A · ROE 5.1%. (2024–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Market Cap | $367M | $218M | — |
| Enterprise Value | $367M | $218M | — |
| P/E Ratio → | 57.32 | 54.58 | — |
| P/S Ratio | — | — | — |
| P/B Ratio | 0.98 | 0.94 | — |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | — |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| ROE | 5.1% | 5.1% | — |
| ROA | 5.0% | 5.0% | -87.0% |
| ROIC | -1.8% | -1.8% | — |
| ROCE | -2.4% | -2.4% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / Equity | — | — | — |
| Debt / EBITDA | — | — | 902.35 |
| Net Debt / Equity | — | -0.00 | — |
| Net Debt / EBITDA | — | — | 661.00 |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($6137) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Current Ratio | 0.03 | 0.03 | 6.27 |
| Quick Ratio | 0.03 | 0.03 | 6.27 |
| Cash Ratio | 0.02 | 0.02 | 1.70 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Earnings Yield | 1.7% | 1.8% | — |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | — |
| Shares Outstanding | — | $21M | $9M |
Includes 30+ ratios · 2 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DMAA stock.
Drugs Made In America Acquisition Corp. Ordinary Shares's current P/E ratio is 57.3x. The historical average is 54.6x. This places it at the 100th percentile of its historical range.
Drugs Made In America Acquisition Corp. Ordinary Shares's return on equity (ROE) is 5.1%. The historical average is 5.1%.
Based on historical data, Drugs Made In America Acquisition Corp. Ordinary Shares is trading at a P/E of 57.3x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Insolvency and liquidation risk
Metrics are mathematically derived from official filings.
Valuation Disconnected From Operational Reality
According to recent SEC filings, DMAA's P/E ratio of 56.00 appears largely detached from fundamental performance, as the company lacks any active revenue streams or sustainable earnings power to justify such a multiple in the context of its current pre-combination shell status and limited capital base.
The elevated P/E ratio likely reflects non-operating accounting adjustments rather than genuine growth prospects, rendering traditional valuation metrics largely irrelevant for this entity. Investors should monitor the fact that the company's market pricing appears to be driven by speculative interest in a potential reverse merger rather than any underlying business value.
Critical Liquidity Constraints Threaten Viability
Based on the most recent quarterly filings, the company's current ratio has collapsed to 0.03, which indicates that DMAA lacks the necessary liquid assets to meet its immediate administrative obligations, a trend that underscores the extreme vulnerability of its current financial position and ongoing operational sustainability.
This liquidity profile suggests that the company is effectively unable to cover its basic regulatory and compliance costs without external support or further dilution. The near-zero quick ratio confirms that the entity possesses virtually no deployable capital, leaving it highly susceptible to involuntary liquidation or delisting.
Capital Decay Reflects Structural Inactivity
As reported in financial statements, DMAA's ROIC has consistently trended in negative territory, with recent periods showing values near -0.7%, illustrating a persistent failure to generate any return on the capital invested by shareholders while the entity remains in a dormant, pre-combination shell state.
The inability to achieve positive returns on capital is a direct consequence of the company's lack of operational activity and the ongoing erosion of its cash reserves through fixed administrative expenses. This trend suggests that capital is being consumed rather than compounded, which warrants extreme caution for any prospective investor.
Misleading Asset Valuation Obscures Insolvency
As indicated by the discrepancy between total assets of $239.9 million and a cash balance of only $6,137 in 2025Q4, the headline asset figure appears highly misleading, likely masking the absence of tangible, deployable capital required for a viable pharmaceutical acquisition or long-term business development.
The most commonly misapplied metric for this business model is the 'Total Assets' figure, which fails to distinguish between restricted trust assets and actual working capital available for operations. Analysts should instead focus on the 'Cash and Cash Equivalents' line item to assess the true runway remaining for the company to secure a merger target.